Supporting Women Towards Risk Reduction and Management of Gynecological and Obstetric Issues (SF-CSAPA)

March 12, 2024 updated by: University Hospital, Strasbourg, France

How to Support Women Already Followed Within the CSAPA Towards Risk Reduction and Management of Gynecological and Obstetric Issues

The health of women who use drugs is a real public health issue where the midwife has an important role to play in the multidisciplinary support of the Center for Care, Support and Prevention in Addictology (CSAPA).

The main objective is to identify the needs and expectations of the women received in terms of reducing risks and damage at the gynecological and obstetric level.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

25

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Strasbourg, France, 67091
        • Service d'addictologie - CHU de Strasbourg - France

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

- Adult women (≥ 18 years old) followed at the Center for Care, Support and Prevention in Addictology (CSAPA) of the University Hospitals of Strasbourg

Description

Eligibility Criteria:

  • Adult women (≥ 18 years old)
  • Followed at the Center for Care, Support and Prevention in Addictology (CSAPA) of the University Hospitals of Strasbourg
  • Speaking and understanding French
  • Agreeing to participate anonymously in this study

Exclusion Criteria:

  • Refusal to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Retrospective description of the needs and expectations of women in terms of gyneco-obstetric risk reduction
Time Frame: Through study completion, an average of 1 months
Through study completion, an average of 1 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 17, 2023

Primary Completion (Actual)

September 17, 2023

Study Completion (Actual)

September 17, 2023

Study Registration Dates

First Submitted

December 18, 2023

First Submitted That Met QC Criteria

January 5, 2024

First Posted (Actual)

January 8, 2024

Study Record Updates

Last Update Posted (Actual)

March 13, 2024

Last Update Submitted That Met QC Criteria

March 12, 2024

Last Verified

December 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 9021

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gynecologic Nursing

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe